News | March 03, 2024
Briefs: SMS Pharmaceuticals and Vimta Labs
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The plant will drive pharmaceutical innovation in the Northeastern India
The facility will accommodate over 1,500 employees
Subscribe To Our Newsletter & Stay Updated
